Published in Nat Rev Nephrol on July 30, 2013
[Hereditary renal tumors : More common than expected?]. Pathologe (2016) 1.38
Oncogenic micro-RNAs and Renal Cell Carcinoma. Front Oncol (2014) 0.92
Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology. Chin J Cancer Res (2016) 0.91
Von Hippel-Lindau disease. Handb Clin Neurol (2015) 0.89
β-catenin links von Hippel-Lindau to aurora kinase A and loss of primary cilia in renal cell carcinoma. J Am Soc Nephrol (2014) 0.86
WSB1 promotes tumor metastasis by inducing pVHL degradation. Genes Dev (2015) 0.84
Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association. Virchows Arch (2015) 0.83
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients. Orphanet J Rare Dis (2015) 0.81
Serum and urine biomarkers for human renal cell carcinoma. Dis Markers (2015) 0.80
Sorafenib treatment for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel- Lindau disease: A case report and literature review. Can Urol Assoc J (2015) 0.78
Insulin receptor expression in clear cell renal cell carcinoma and its relation to prognosis. Yonsei Med J (2014) 0.78
Metabolic reprogramming in clear cell renal cell carcinoma. Nat Rev Nephrol (2017) 0.75
Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation. Oncotarget (2015) 0.75
Managing Renal Cell Carcinoma Associated Paraneoplastic Syndrome with Nephron-sparing Surgery in a Patient with von Hippel-Lindau. Urol Case Rep (2017) 0.75
From headache to kidney tumor; an example of von Hippel- Lindau disease. J Renal Inj Prev (2015) 0.75
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Renal-cell carcinoma. N Engl J Med (1996) 11.46
Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer (2010) 10.61
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet (1994) 10.14
Rising incidence of renal cell cancer in the United States. JAMA (1999) 9.57
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell (2005) 9.33
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet (2002) 8.19
Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med (2002) 6.94
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell (2002) 6.32
von Hippel-Lindau disease. Lancet (2003) 6.20
Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer (2002) 5.63
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 5.46
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10
HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell (2002) 4.82
Clinical features and natural history of von Hippel-Lindau disease. Q J Med (1990) 4.71
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA (2004) 4.52
SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science (2009) 3.72
Von Hippel-Lindau disease: a genetic study. J Med Genet (1991) 3.61
The genetic basis of cancer of the kidney. J Urol (2003) 3.45
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet (1991) 3.10
HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet (2002) 3.07
von Hippel-Lindau disease. Medicine (Baltimore) (1997) 2.89
Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst (2008) 2.89
Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med (1979) 2.82
Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat (1996) 2.80
Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat (2010) 2.75
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69
Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab (2000) 2.52
Metastatic potential in renal cell carcinomas ≤7 cm: Swedish Kidney Cancer Quality Register data. Eur Urol (2011) 2.45
Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet (2003) 2.43
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol (2010) 2.42
The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol (2004) 2.32
pVHL and GSK3beta are components of a primary cilium-maintenance signalling network. Nat Cell Biol (2007) 1.97
Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol (2007) 1.86
Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol (1999) 1.84
Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int (2011) 1.83
Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur Urol (2012) 1.79
Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum Mutat (2004) 1.78
A genetic register for von Hippel-Lindau disease. J Med Genet (1996) 1.61
Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol (2001) 1.45
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol (2012) 1.45
Feasibility and outcomes of repeat partial nephrectomy. J Urol (2008) 1.41
Targeted drugs for metastatic renal cell carcinoma. Lancet (2007) 1.36
Somatic loss of maternal chromosome 11 causes parent-of-origin-dependent inheritance in SDHD-linked paraganglioma and phaeochromocytoma families. Oncogene (2004) 1.32
New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am (2011) 1.31
The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol (1992) 1.27
Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol (1998) 1.25
Renal tumors associated with germline SDHB mutation show distinctive morphology. Am J Surg Pathol (2011) 1.21
Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol (2006) 1.21
Life expectancy in hereditary cancer predisposing diseases: an observational study. J Med Genet (2012) 1.20
VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am J Surg Pathol (2010) 1.19
Oncological outcomes of partial nephrectomy for multifocal renal cell carcinoma greater than 4 cm. J Urol (2010) 1.18
Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med (2006) 1.16
Genetic screening for pheochromocytoma: should SDHC gene analysis be included? J Med Genet (2007) 1.15
Renal tumors and hereditary pheochromocytoma-paraganglioma syndrome type 4. N Engl J Med (2011) 1.14
Genotype-phenotype correlations in VHL exon deletions. Am J Med Genet A (2009) 1.06
Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3. Endocr Relat Cancer (2012) 1.05
Results of renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Transplantation (1997) 1.03
Characterization of the renal pathology of a familial form of renal cell carcinoma associated with von Hippel-Lindau disease: clinical and molecular genetic implications. J Urol (1995) 0.96
Central nervous system manifestations in VHL: genetics, pathology and clinical phenotypic features. Fam Cancer (2005) 0.95
Patterns of intervention for renal lesions in von Hippel-Lindau disease. BJU Int (2008) 0.95
Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma. Urol Int (2011) 0.93
Hereditary causes of kidney tumours. Eur J Clin Invest (2010) 0.92
An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. Am J Hum Genet (1998) 0.89
Retinal angiomatosis in von Hippel-Lindau disease: a longitudinal ophthalmologic study. Ophthalmology (2006) 0.89
Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implications. Fam Cancer (2005) 0.87
Local recurrence after nephron-sparing surgery in von Hippel-Lindau disease. Urology (2007) 0.87
Management of advanced renal cancer. Kidney Int (2005) 0.84
Nephron sparing surgery for renal cell carcinoma and von Hippel-Lindau's disease: a single center experience. J Urol (2003) 0.84
Genetic evaluation of von Hippel-Lindau disease for early diagnosis and improved prognosis. Int Urol Nephrol (2007) 0.83
Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Hum Genet (2000) 0.81
Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease previously undergoing a radical nephrectomy or repeated nephron-sparing surgery. Acta Radiol (2011) 0.81
Percutaneous radio frequency ablation of renal tumors in patients with von Hippel-Lindau disease: preliminary results. J Urol (2010) 0.80
Progress in nephron sparing therapy for renal cell carcinoma and von Hippel-Lindau disease. J Urol (2011) 0.79
Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up. Fam Cancer (2012) 0.77
Management of renal tumors in Von Hippel-Lindau disease by percutaneous CT fluoroscopic guided radiofrequency ablation: preliminary results. Fam Cancer (2011) 0.76
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
Spatio-temporal transcriptome of the human brain. Nature (2011) 9.19
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med (2002) 6.94
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med (2007) 6.47
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA (2004) 4.52
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet (2010) 3.99
Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet (2002) 3.89
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res (2008) 3.41
Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res (2012) 3.33
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Validation of proposed DSM-5 criteria for autism spectrum disorder. J Am Acad Child Adolesc Psychiatry (2011) 2.72
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet (2007) 2.64
Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA (2005) 2.59
A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet (2010) 2.59
PTEN hamartoma tumor syndrome: an overview. Genet Med (2009) 2.44
Protean PTEN: form and function. Am J Hum Genet (2002) 2.43
Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet (2003) 2.43
Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA (2010) 2.36
Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients. Surgery (2006) 2.35
Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol (2005) 2.34
The nuclear affairs of PTEN. J Cell Sci (2008) 2.34
From developmental disorder to heritable cancer: it's all in the BMP/TGF-beta family. Nat Rev Genet (2003) 2.26
Familial hyperparathyroidism: surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery (2008) 2.26
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol (2002) 2.16
Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol (2007) 2.16
Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer (2006) 2.13
A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab (2006) 2.10
Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens (2006) 2.09
Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer (2002) 2.02
SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. Am J Hum Genet (2008) 2.00
A time study of cancer genetic counselors using a genetic counselor-only patient care model versus a traditional combined genetic counselor plus medical geneticist care model. J Natl Compr Canc Netw (2013) 2.00
Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. Radiology (2002) 1.96
Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden-like syndromes. Am J Hum Genet (2008) 1.96
Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology (2010) 1.96
Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet (2003) 1.94
APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci U S A (2002) 1.89
Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron (2013) 1.87
Alu-Alu recombination underlies the vast majority of large VHL germline deletions: Molecular characterization and genotype-phenotype correlations in VHL patients. Hum Mutat (2009) 1.85
Highly penetrant hereditary cancer syndromes. Oncogene (2004) 1.84
Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am J Hum Genet (2012) 1.84
Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res (2005) 1.84
Imaging cortical anatomy by high-resolution MR at 3.0T: detection of the stripe of Gennari in visual area 17. Magn Reson Med (2002) 1.83
Re-evaluating acridine orange for rapid flow cytometric enumeration of parasitemia in malaria-infected rodents. Cytometry A (2007) 1.81
Nephrocystin specifically localizes to the transition zone of renal and respiratory cilia and photoreceptor connecting cilia. J Am Soc Nephrol (2006) 1.79
Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.78
Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets. Cancer Res (2004) 1.76
Frequency of germline genomic homozygosity associated with cancer cases. JAMA (2008) 1.67
Unusual features in a patient with neurofibromatosis type 1: multiple subcutaneous lipomas, a juvenile polyp in ascending colon, congenital intrahepatic portosystemic venous shunt, and horseshoe kidney. Am J Med Genet A (2004) 1.67
18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging (2003) 1.65
Prospective comparison of family medical history with personal genome screening for risk assessment of common cancers. Eur J Hum Genet (2012) 1.62
Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma. JAMA (2007) 1.60
Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet (2008) 1.59
Multiple endocrine neoplasia type 2: an overview. Genet Med (2011) 1.58
Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab (2007) 1.57
BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum Mol Genet (2003) 1.54
Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer (2006) 1.53
Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 1.53
Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology (2013) 1.49
PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene (2004) 1.49
Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene (2003) 1.47
One hundred consecutive kidney transplantations with simultaneous ipsilateral nephrectomy in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2012) 1.47
Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A (2007) 1.46
LASP-1, a novel urinary marker for detection of bladder cancer. Urol Oncol (2012) 1.44
Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients. World J Surg (2006) 1.42
Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet (2003) 1.41
Cowden syndrome. Semin Oncol (2007) 1.39
Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. Am J Hum Genet (2007) 1.39
Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res (2009) 1.38
Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol (2004) 1.37
The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet (2002) 1.36
Defining phenotypes and cancer risk in hyperplastic polyposis syndrome. Dis Colon Rectum (2011) 1.36
Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer Res (2007) 1.34
Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev (2006) 1.33
Trabectome surgery for primary and secondary open angle glaucomas. Graefes Arch Clin Exp Ophthalmol (2013) 1.33
Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) has nuclear localization signal-like sequences for nuclear import mediated by major vault protein. Cancer Res (2005) 1.33
Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol (2013) 1.33
Association of human herpesvirus-6B with mesial temporal lobe epilepsy. PLoS Med (2007) 1.32
Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation. Am J Hum Genet (2006) 1.31
Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med (2009) 1.30
The approach to the patient with paraganglioma. J Clin Endocrinol Metab (2009) 1.30
Optimized high gradient magnetic separation for isolation of Plasmodium-infected red blood cells. Malar J (2010) 1.29
Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab (2003) 1.28
Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat (2009) 1.26
Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer (2006) 1.26
Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations. J Clin Endocrinol Metab (2011) 1.25
Analysis of prevalence and degree of macrocephaly in patients with germline PTEN mutations and of brain weight in Pten knock-in murine model. Eur J Hum Genet (2011) 1.25
Evidence of MEN-2 in the original description of classic pheochromocytoma. N Engl J Med (2007) 1.24